BMS’ patent bid for Hep C treatment Daclatasvir Challenged

BMS’ patent bid for Hep C treatment Daclatasvir Challenged

2nd May 2015 – Stepping up efforts to counter patents on life-saving medicines, three civil society groups working to increase access to affordable, life-saving Hepatitis C (HCV) medicines, have challenged Bristol-Myers Squibb (BMS’) pending patent application on Daclatasvir before the Delhi Patent Office. The pre-grant opposition filed by Hepatitis Coalition, Nagaland (HepCon), Sankalp Rehabilitation Trust (Sankalp Trust), Mumbai and Asia Pacific Network of Positive People (APN+), all of whom are represented by the Lawyers Collective

Daclatasvir, a direct acting antiviral (DAA) is a part of the class of new oral treatments to treat chronic HCV. It works to block the NS5A protein in the HCV without which the virus cannot replicate. In combination with other oral DAAs like Sofosbuvir, it has shown very promising treatment outcomes moving towards an all-oral, simplified and well-tolerated regimen from the current treatment regimen of painful and side-effect laden pegylated interferon injections……read the press release

/ News

Share the Post